Histone deacetylase inhibitors
US7842727B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 20, 2006 |
| Grant date | Nov 30, 2010 |
| Priority date | — |
| Expiry date | Sep 29, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, genetic disorders, e.g. Huntington's disease and spinal muscular atrophy and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.